Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 6/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100797 | 0.93 | FGFR2 (0.35) | — | |
| SCHEMBL4091530 | 0.90 | MAP4K1 (0.38) | CRHR1DHFRCTSAMAP4K1 | |
| SCHEMBL4105401 | 0.90 | MAPT (0.34) | CRHR1DHFRMAP4K1KDM4E | |
| SCHEMBL4103149 | 0.89 | TRPA1 (0.32) | — | |
| SCHEMBL4102639 | 0.87 | CYP2C9 (0.35) | CRHR1DHFRHCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL4101972 | 0.86 | CRHR1 (0.33) | CRHR1DHFRKDM4E | |
| SCHEMBL4109802 | 0.85 | CRHR1 (0.34) | CRHR1DHFRMAP4K1 | |
| SCHEMBL4106287 | 0.84 | SMN1; SMN2 (0.35) | CRHR1DHFRKDM4EALDH1A1 | |
| SCHEMBL4096321 | 0.84 | DHFR (0.31) | DHFRMAP4K1 | |
| SCHEMBL4098013 | 0.84 | ALPL (0.33) | CRHR1HCRTR1HCRTR2MAP4K1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | claimed |
| EP-1903045-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-03-26 | — | — | EP | claimed |
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1903045-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MC2R, CRHR1, AVPR2 | CRHR1 2/4885DHFR 1568/4885CTSA 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.